Please assess the completion status of the following clinical trial:

Trial Title: Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Old \< 18 years, male or female.~* Chronic myeloid leukaemia confirmed on the cytogenetic level by the presence of the translocation t(9; 22) (q34; q11) or by the presence of transcript BCR-ABL in the event of absence of description of the translocation t(9; 22) (q34; q11).~* Chronic phase of a chronic myeloid leukaemia~* Absence of extra-medullary disease (except for a hepatomegaly and/or of a splenomegaly).~* Absence of any former treatment of chronic myeloid leukaemia except for hydroxyurea.~* Stop of hydroxyurea at least week before the beginning of the imatinib mesylate.~* Diagnosis of chronic myeloid leukaemia in chronic phase recent (less than 2 months).~* Score of Lansky ≥ 60.~* Effective contraception among patients in age to procreate.~* Written voluntary informed consent of the two parents or the legal guardian.~Exclusion Criteria:~* Patients with grade 3 / 4 cardiac disease.~* Pathology cardiac, pulmonary, hepatic, renal or neurological of grade \> 2 (WHO).~* Participation in a clinical trial in the 28 days preceding the beginning by the treatment.~* Impossible Follow-up during at least 2 years, patient not compliant.~* Expectant mother or nursing.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).